The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer
- Thread starter Educator
- Start date